Merck and the European Molecular Biology Laboratory announce drug discovery collaboration
- Details
- Category: Merck Group
Merck, a leading science and technology company, announced today that it has entered into a research collaboration focused on cancer metabolism with the European Molecular Biology Laboratory (EMBL), located in Heidelberg, Germany.
AstraZeneca enters licensing agreement with China Medical System Holdings for hypertension medicine
- Details
- Category: AstraZeneca
AstraZeneca today announced it has entered into a licensing agreement with China Medical System Holdings Ltd (CMS) for the commercialisation rights in China to its calcium channel blocker, Plendil (felodipine). Plendil was first approved in China in 1995 for the treatment of hypertension or high blood pressure and in 2015 achieved Product Sales of $189 million.
Acalabrutinib recommended for orphan drug designation in Europe for three indications
- Details
- Category: AstraZeneca
AstraZeneca and Acerta Pharma BV, a company in which AstraZeneca has a majority equity investment, have announced that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) adopted three positive opinions recommending acalabrutinib (ACP-196) for designation as an orphan medicinal product.
Daiichi Sankyo announces commencement of clinical trials in Japan for Duchenne muscular dystrophy treatment
- Details
- Category: Daiichi Sankyo
Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced today that administration of the Duchenne muscular dystrophy (hereafter, DMD) treatment drug DS-5141b (hereafter, the Drug), which is jointly developing with the Orphan Disease Treatment Institute Co., Ltd. (hereafter, ODTI), to the first subject has begun in the first clinical trial in Japan.
Johnson & Johnson issues call for innovative ideas to reduce HIV infections in Sub-Saharan Africa
- Details
- Category: Johnson & Johnson
Johnson & Johnson (NYSE: JNJ) issued a call for innovative ideas as part of the DREAMS Innovation Challenge, which is supported by the U.S. President's Emergency Plan for AIDS Relief (PEPFAR), Janssen Pharmaceutica, NV, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, and ViiV Healthcare.
Four inspiring innovations which help reduce child deaths in developing countries share $1 million prize from GSK and Save the Children
- Details
- Category: GlaxoSmithKline
GSK and Save the Children today revealed the winners of their third annual US$1 million Healthcare Innovation Award, which recognises innovations from developing countries that are helping to reduce deaths among children under five.
Novartis shareholders approve all resolutions proposed by Board of Directors
- Details
- Category: Novartis
More than 97% of Novartis shareholders today followed the Board of Directors' recommendations for all proposed resolutions at the Group's Annual General Meeting. A total of 1,776 shareholders were present at the meeting held in Basel, representing approximately 61.6% of the issued shares of Novartis.
More Pharma News ...
- Bristol-Myers Squibb completes previously announced sale of its HIV R&D portfolio to ViiV Healthcare
- Brilique (ticagrelor) approved in EU for extended treatment of patients with history of heart attack
- Alcon expands leadership position in treating glaucoma through acquisition of Transcend Medical, Inc.
- U.S. FDA grants Breakthrough Therapy Designation for Roche's investigational medicine ocrelizumab in primary progressive multiple sclerosis
- Bristol-Myers Squibb and Dana-Farber Cancer Institute enter into a collaboration agreement
- UCB and Baylor College of Medicine launch strategic alliance in neurodegeneration
- Sandoz advances its biosimilars program with EMA acceptance of regulatory submission for biosimilar pegfilgrastim